<DOC>
	<DOCNO>NCT01206777</DOCNO>
	<brief_summary>The purpose study assess feasibility 60 minute rapid infusion rituximab protocol institution 's outpatient infusion center .</brief_summary>
	<brief_title>Feasibility Study 60 Minute Rapid Infusion Rituximab Protocol Patients With B-cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age 1889 Diagnosis indolent intermediate grade Bcell malignancy Patients receive rituximabbased therapy dose 375mg/m2 , regardless weight First dose give within 3 month second dose Infusion schedule outpatient administration The Arthur G. James Cancer Hospital Richard J. Solove Research Institute Diagnosis aggressive lymphoma Absolute lymphocyte count &gt; 10 x 103 cells/ÂµL New York Heart Association ( NYHA ) classification Grade II great congestive heart failure Enrolled another clinical trial Allergy murinecontaining medication Grade III IV hypersensitivity reaction initial infusion rituximab Prisoners Pregnant woman Mentally physically unable give consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Hypersensitivity Reactions</keyword>
	<keyword>B-cell malignancy</keyword>
</DOC>